Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV–HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy

Figures & data

Figure 1 Details of the enrolled population.

Table 1 Baseline Characteristics of the Studied Population (n=80)

Characteristics
Mean age (SD)^a years	34.1 (9.2)
Gender n (%)
Male	57 (71.2%)
Female	23 (28.8%)
Median baseline CD4 count cells/mm^3 (IQR) ^b	341 (218−506)
Mean HCV viral load in log10IU/mL (SD)	6.1 (0.97)
Mean HIV viral load in log 10 IU/mL	<1.6
Genotype n (%)
Genotype 1 [1a]	12 (15%)
Genotype 3 [3a/3b/3g]	32 [12/18/2] (40%)
Genotype 6 [6n/6v/6u/6xa]	36 [15/2/2/17] (45%)
BL-RAS^c
Present	19 (23.7%)
Absent	61(76.2%)

Notes: ^aSD, standard deviation; ^bIQR, interquartile range; ^cBL-RAS, baseline resistance associated substitutions.

Table 2 Factors Associated with Treatment Failure

Factors	SVR Attained (n=63)	SVR Not Attained (n=17)	Unadjusted OR^a (95% CI)	p-value
	n(%)	n(%)
Age
<30 years	18 (56.2)	14 (43.8)	1	<0.001
>30years	45 (93.8)	3 (6.2)	11.6 (3.0–45.5)
Gender
Male	41 (71.9)	16 (28.1)	1	0.009
Female	22 (95.6)	1 (4.4)	8.6 (1.1–69.1)
Genotype (Gt)
Gt1	10 (83.3)	2 (16.7)	2.8 (0.5–15.3)	0.107
Gt3	18 (64.3)	10 (35.7)	1
Gt6	31 (86.1)	5 (16.9)	3.4 (1.0–11.7)
BL-RAS at NS5a
No	50 (80.8)	11 (19.2)	1.9 (0.6–6.4)	0.282
Yes	13 (68.4)	6 (31.6)	1
CD4 count (cells/mm^3)
<350	28 (82.4)	6 (17.6)	1	0.495
≥350	35 (76.1)	11 (23.9)	0.68 (0.2–2.1)

Note: ^aOR, odds ratio.

Table 3 Distribution of Baseline Resistance Associated Substitutions (BL-RAS)

S. No	Genotype	Subtype	BL-RAS at NS5a ^a	BL- RAS at NS5b^a	Prediction for Drug Resistance^c	SVR^b	SVR RAS at NS5a	SVR RAS at NS5b	After Rereatment
1.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
2.	3	3b	31M,30K	None	Resistant	Not attained	None	None	SVR attained
3.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
4.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
5.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
6.	6	6xa	93A	None	Not known	Attained	-	-	-
7.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
8.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
9.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
10.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
11.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
12.	3	3b	31M,30K	None	Resistant	Not attained	31M,30K	None	Died
13.	3	3b	31M,30K	None	Resistant	Not attained	31M,30K	None	SVR attained
14.	3	3a	31M,30K	None	Resistant	Not attained	None	None	SVR attained
15.	1	1a	30H	None	Not known	Attained	-	-	-
16.	3	3b	31M,30K	None	Resistant	Attained	-	-	-
17.	3	3b	31M,30K	None	Resistant	Not attained	31M,30K	None	SVR attained
18.	3	3a	93H	None	Resistant	Not attained	93H	None	Lost to follow-up
19.	3	3b	31M,30K	None	Resistant	Attained	-	-	-

Notes: ^aBL-RAS, baseline resistance associated substitutions; ^bSVR, sustained virological response; ^cas per the information of online tool (reference 15).